<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEOSPORIN- neomycin sulfate, polymyxin b sulfate and gramicidin solution </strong><br>Monarch Pharmaceuticals, Inc.<br></p></div>
<h1> NEOSPORIN<span class="Sup">®</span> Ophthalmic Solution Sterile<br>(neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_6f8bb6b6-49e4-4dd2-b27d-312d2d2123cf"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Neosporin Ophthalmic Solution (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution) is a sterile antimicrobial solution for ophthalmic use. Each mL contains: neomycin sulfate equivalent to 1.75 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and gramicidin 0.025 mg. The vehicle contains alcohol 0.5%, thimerosal 0.001% (added as a preservative), and the inactive ingredients propylene glycol, polyoxyethylene polyoxypropylene compound, sodium chloride, and Water for Injection.</p>
<p>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of <span class="Italics">Streptomyces fradiae</span> Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<p><img alt="ChemStructure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33e9b6d3-2b2b-4036-dd89-47177e23fcfe&amp;name=b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2-01.jpg"></p>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span> which are produced by the growth of <span class="Italics">Bacillus polymyxa </span> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:</p>
<p><img alt="ChemStructure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33e9b6d3-2b2b-4036-dd89-47177e23fcfe&amp;name=b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2-02.jpg"></p>
<p>Gramicidin (also called Gramicidin D) is a mixture of three pairs of antibacterial substances (Gramicidin A, B, and C) produced by the growth of Bacillus brevis Dubos (Fam. Bacillaceae). It has a potency of not less than 900 µg of standard gramicidin per mg. The structural formulae are:</p>
<p><img alt="ChemStructure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33e9b6d3-2b2b-4036-dd89-47177e23fcfe&amp;name=b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_456cf23f-5ddf-4a15-8929-d3e135fb8aa5"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and gramicidin.</p>
<p>Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code. </p>
<p>Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane. </p>
<p>Gramicidin is bactericidal for a variety of gram-positive organisms. It increases the permeability of the bacterial cell membrane to inorganic cations by forming a network of channels through the normal lipid bilayer of the membrane.</p>
<p>Neomycin sulfate, polymyxin B sulfate, and gramicidin together are considered active against the following microorganisms: <span class="Italics">Staphylococcus aureus</span>, streptococci, including <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/Enterobacter </span> species, <span class="Italics">Neisseria</span> species, and <span class="Italics">Pseudomonas aeruginosa</span>. The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c84daf8b-4dd6-43b0-9a61-537cca26a2a2"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the external eye and its adnexa caused by susceptible bacteria. Such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> encompass <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c069ee39-cc7d-413b-973f-80b695aaaa56"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NEOSPORIN Ophthalmic Solution is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_56ae95b0-7ec0-4108-8737-ac54f6382f16"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. NEOSPORIN Ophthalmic Solution should never be directly introduced into the anterior chamber of the eye or injected subconjunctivally. </p>
<p>Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Application of products containing these ingredients should be avoided for the patient thereafter (see <span class="Bold"><a href="#i4i_precautions_general_id_05a1986a-a5f6-4d93-af7e-6de339f1bef4">PRECAUTIONS:General</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_57f93093-9434-4bf7-b612-8a945223d4e8"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_05a1986a-a5f6-4d93-af7e-6de339f1bef4"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with other antibiotic preparations, prolonged use of NEOSPORIN Ophthalmic Solution may result in overgrowth of nonsusceptible organisms including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate measures should be initiated. </p>
<p><span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to NEOSPORIN Ophthalmic Solution may also develop. If <span class="product-label-link" type="condition" conceptid="4145093" conceptname="Purulent discharge">purulent discharge</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> becomes aggravated, the patient should discontinue use of the medication and consult a physician. </p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see <span class="Bold"><a href="#i4i_info_patients_id_6dab36e3-bce5-4ccb-ae86-1306cf68b8e6">PRECAUTIONS:Information for Patients</a></span>). </p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: kanamycin, paromomycin, streptomycin, and possibly gentamicin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6dab36e3-bce5-4ccb-ae86-1306cf68b8e6"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated products (see <span class="Bold"><a href="#i4i_precautions_general_id_05a1986a-a5f6-4d93-af7e-6de339f1bef4">PRECAUTIONS:General</a></span>). </p>
<p>If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients. </p>
<p>Keep tightly closed when not in use. Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_78cc7b6e-b4ce-49f0-b08a-d49bce314326"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or gramicidin. Treatment of cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 µg/mL) tested. However, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. </p>
<p>Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_304c25bd-c386-44ba-8b3b-75796d12b447"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_e20ec623-d918-43a5-bec7-c373ebf6d94c"></a><a name="section-6.4.1"></a><p></p>
<h3><span class="Italics"><span class="Bold">Teratogenic Effects</span></span></h3>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate, or gramicidin. It is also not known whether NEOSPORIN Ophthalmic Solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. NEOSPORIN Ophthalmic Solution should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6861add6-63fd-45cc-a348-b4997f089b5e"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEOSPORIN Ophthalmic Solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_dd602295-22eb-4e6e-8e68-f7629b175719"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_34b601ad-04f8-459a-884c-4f2d10226da5"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of NEOSPORIN<span class="Sup">®</span> Ophthalmic Solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a90d0804-580c-4a79-8244-21c12f2c5f83"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions have occurred with the anti-infective components of NEOSPORIN Ophthalmic Solution. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <span class="Bold"><a href="#i4i_warnings_id_56ae95b0-7ec0-4108-8737-ac54f6382f16">WARNINGS</a></span>). More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely. </p>
<p>Local irritation on instillation has also been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2c3e89ed-510d-4432-bd1c-c2da56cfa8c1"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one or two drops into the affected eye every 4 hours for 7 to 10 days. In severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, dosage may be increased to as much as two drops every hour.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e69447fb-03d3-4a67-8192-d1427c99b1e6"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Drop Dose<span class="Sup">®</span> of 10 mL (plastic dispenser bottle) (<span class="Bold">NDC</span> 61570-045-10).</p>
<p><span class="Bold">Rx only. </span></p>
<p>Store at 15° to 25°C (59° to 77°F) and protect from light. </p>
<p>Prescribing Information as of July 2004.</p>
<p>Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620</p>
<p>(A wholly owned subsidiary of King Pharmaceuticals, Inc.)</p>
<p>Manufactured by: DSM Pharmaceuticals, Inc., Greenville, NC 27834</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ea1485ac-276a-465d-9ff6-d28d10ff3cf7"></a><a name="section-10"></a><p></p>
<h1>LabelGraphics1</h1>
<div class="Figure"><img alt="LabelGraphics1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33e9b6d3-2b2b-4036-dd89-47177e23fcfe&amp;name=b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1d0ef108-9fa9-461f-bfdf-ff9fdece9bae"></a><a name="section-11"></a><p></p>
<h1>LabelGraphics2</h1>
<div class="Figure"><img alt="LabelGraphics2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=33e9b6d3-2b2b-4036-dd89-47177e23fcfe&amp;name=b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEOSPORIN 		
					</strong><br><span class="contentTableReg">neomycin and polymyxin b sulfates and gramicidin solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61570-045</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">1.75 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 [iU]  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GRAMICIDIN</strong> (GRAMICIDIN) </td>
<td class="formItem">GRAMICIDIN</td>
<td class="formItem">0.025 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-045-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060582</td>
<td class="formItem">04/11/1955</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Monarch Pharmaceuticals, Inc.
							(809587413)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2</div>
<div>Set id: 33e9b6d3-2b2b-4036-dd89-47177e23fcfe</div>
<div>Version: 2</div>
<div>Effective Time: 20110719</div>
</div>
</div> <div class="DistributorName">Monarch Pharmaceuticals, Inc.</div></p>
</body></html>
